Adc Therapeutics SA (ADCT) intrinsic value & 10-year financials
Adc Therapeutics SA (ADCT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 2.8% a year to $81.4M, with an average return on invested capital of -1.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.40
- Market cap
- $177.9M
- Revenue (FY2025)
- $81.4M
- Revenue growth (9-yr CAGR)
- 2.8%
- ROIC (10-yr avg)
- -1.4%
- Free cash flow (FY2025)
- -$141.4M
ADCT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $81.4M | -$142.6M | -$1.12 | -$141.4M | -149.3% | 27.3% |
| FY2024 | $70.8M | -$157.8M | -$1.62 | -$124.7M | -184.4% | 30.3% |
| FY2023 | $69.1M | -$240.1M | -$2.94 | -$121.9M | -240.4% | 50.5% |
| FY2022 | $74.9M | -$157.1M | -$2.01 | -$139.0M | -164.7% | 53.0% |
| FY2021 | — | -$230.0M | — | -$236.8M | — | 102.1% |
| FY2020 | — | -$246.3M | — | -$169.5M | — | -110.3% |
| FY2019 | — | -$116.5M | — | -$121.9M | — | -98.1% |
| FY2018 | — | -$123.1M | — | -$122.3M | — | -65.6% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ADC Therapeutics SA revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ADC Therapeutics SA has historically struggled to out-earn its cost of capital, averaging just -1.3% ROIC.
ADC Therapeutics SA has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ADC Therapeutics SA is modeled at 2.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-13.61 per share.